Sociodemographic characteristics and key outcomes of LHIV-Manitoba cohort participants, as compared with Manitoba HIV Program’s client population
| LHIV-Manitoba cohort (N=890) | Manitoba HIV Program (N=1357) | P value | |||
| n | % | n | % | ||
| Age (years) on 31 March 2019 or at time of death | |||||
| <18 | 0 | 0 | 2 | 0.2 | 0.245 |
| 18–24 | 10 | 1.1 | 46 | 3.4 | 0.001 |
| 25–39 | 178 | 20.0 | 358 | 26.4 | 0.001 |
| 40–64 | 621 | 69.8 | 871 | 64.2 | 0.006 |
| ≥65 | 81 | 9.1 | 78 | 5.8 | 0.003 |
| Mean (SD) | 49.7 (11.9) | 46.8 (12.1) | 0.000 | ||
| Median (IQR) | 49.8 (41.5–57.5) | 46.9 (37.9–55.2) | 0.000 | ||
| Sex | |||||
| Male | 634 | 71.2 | 878 | 64.7 | 0.001 |
| Female | 256 | 28.8 | 478 | 35.2 | 0.002 |
| Self-identified ethnicity* | |||||
| White | 376 | 42.4 | 407 | 36.2 | 0.000 |
| Indigenous (First Nations, Inuit and Métis) | 369 | 41.6 | 448 | 39.9 | 0.000 |
| Sub-Saharan African/Caribbean/black | 97 | 10.9 | 214 | 19.1 | 0.001 |
| Other† | 44 | 5.0 | 54 | 4.8 | 0.307 |
| Region of residence | |||||
| Winnipeg | 719 | 80.8 | 1080 | 79.6 | 0.486 |
| Central and Eastern Manitoba | 48 | 5.4 | 71 | 5.2 | 0.836 |
| Southern Manitoba | 37 | 4.2 | 67 | 4.9 | 0.440 |
| Western Manitoba | 35 | 3.9 | 64 | 4.7 | 0.365 |
| Northern Manitoba | 30 | 3.4 | 46 | 3.4 | 1.000 |
| Out of province | 12 | 1.4 | 21 | 1.6 | 0.705 |
| Unknown/No known address | 9 | 1.0 | 8 | 0.6 | 0.285 |
| Drug coverage at 31 March 2019‡ | |||||
| Out-of-pocket expenses associated with drug plan | 293 | 45.4 | – | – | – |
| No out-of-pocket expenses associated with drug plan | 346 | 53.6 | – | – | |
| Not on treatment/unknown | 6 | 0.9 | – | – | |
| Problematic substance use recorded in clinic file§ | |||||
| Alcohol | 292 | 40.3 | – | – | – |
| Illegal or ‘street’ drugs¶ | 222 | 31.6 | – | – | |
| Alcohol and drugs | 148 | 21.1 | – | – | |
| Has a primary care practitioner§ | 627 | 70.5 | – | – | – |
*Sample sizes may not add up to total participants due to missing data for some variables.
†Includes Latin American, East/Southeast Asian, South Asian and West Asian/North African/Middle Eastern.
‡Variable only collected for participants alive in the fourth quarter of 2018 (n=645).
§Variable only collected for participants alive at cohort enrolment (n=725).
¶Includes cocaine, crack cocaine, heroin, crystal methamphetamine, other hallucinogens (lysergic acid diethylamide (LSD), γ-hydroxybutyric acid (GHB), ketamine, 3,4-methylenedioxymethamphetamine (ecstasy)) and solvents such as Talwin and Ritalin and alkyl nitrates (poppers).